You are here:

Irbesartan (Aprovel®)

Advice

Recommended for restricted use within NHS Scotland.

RECOMMENDATION

Irbesartan, for the treatment of renal disease in patients with hypertension and type 2 diabetes mellitus, is effective, but has not been shown to be any more effective than ACE inhibitors, which are generally less expensive products, and for which there is a strong evidence base in diabetic renal disease and other forms of cardiovascular disease.

Therefore, irbesartan should be considered, along with other angiotensin II antagonists licensed for diabetic renal disease, as an alternative in patients unable to tolerate an ACE inhibitor.

Drug Details

Drug Name: Irbesartan (Aprovel®)
SMC Drug ID: 38/03
Manufacturer: Sanofi-Aventis
Indication: Renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive drug regimen
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Restricted
Date Advice Published: 9 May 2003

Back